Insmed reported $20.08M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Cytokinetics USD 33.34M 3M Mar/2026
DBV Technologies USD 461K 323.71K Mar/2025
Gilead Sciences USD 240M 15M Mar/2026
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 20.08M 517K Mar/2026
Novartis USD 281M 8M Sep/2025
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025